Medigene Presents First Results for Automated Manufacturing of T Cell Receptor Engineered T Cells
23 févr. 2023 08h00 HE
|
Medigene AG
MARTINSRIED, Germany and MUNICH, Germany, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Medigene AG (Medigene, FSE: MDG1, Prime Standard) is an early-stage immuno-oncology platform company focusing on the...
Medigene to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
22 févr. 2023 10h00 HE
|
Medigene AG
MARTINSRIED, Germany and MUNICH, Germany, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the...
Medigene to Present at the 6th Annual CAR-TCR Summit Europe in London
15 févr. 2023 09h00 HE
|
Medigene AG
MARTINSRIED, Germany and MUNICH, Germany, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the...
Medigene AG Appoints Pamela Keck as Vice President of Investor Relations and Corporate Communications
01 févr. 2023 11h35 HE
|
Medigene AG
MARTINSRIED and MUNICH, Germany, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and...
Medigene Receives $3 Million Milestone Payment from 2seventy bio
18 janv. 2023 11h35 HE
|
Medigene AG
Milestone payment is related to the establishment of 2seventy bio’s strategic partnership with JW TherapeuticsPayment provides further validation of Medigene’s end-to-end platform MARTINSRIED,...
Medigene Announces Strategy and Corporate Update
15 nov. 2022 11h35 HE
|
Medigene AG
Company strategy focused on developing differentiated TCR-T therapies from its proprietary “end-to-end” platform to target solid tumors with high unmet needPipeline expansion and acceleration of lead...
Medigene to Take Part in Cell Therapy Panel at the LifeSci Partners 10th Annual Healthcare Corporate Access Event
05 janv. 2021 08h40 HE
|
Medigene AG
MARTINSRIED, Germany and MUNICH, Germany, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Medigene AG (FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell...
Medigene enters Phase I clinical development with its TCR-T immunotherapy MDG1021 in hematological cancers
23 juin 2020 16h46 HE
|
Medigene AG
MDG1021 becomes Medigene’s second proprietary clinical TCR-T candidateClinical trial approval from Dutch regulatory authority Phase I clinical trial in cancer patients suffering from...
Medigene’s PD1-41BB Switch Receptor Enhances TCR-T Cell Activity Towards Solid Tumors
22 juin 2020 09h00 HE
|
Medigene AG
MARTINSRIED, Germany and MUNICH, Germany, June 22, 2020 (GLOBE NEWSWIRE) -- Medigene AG (Medigene, FSE: MDG1), a clinical stage immuno-oncology company focusing on the development of T cell...
Medigene Provides Results for Fiscal Year 2019 and Outlook
26 mars 2020 06h18 HE
|
Medigene AG
MARTINSRIED, Germany and MUNICH, Germany, March 26, 2020 (GLOBE NEWSWIRE) -- Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T...